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Abstract
Background: It has been argued that postoperative pain treatment should be “procedure-specific”, since different
analgesics may have specific effects dependent on the surgical procedure. The aim of the present subgroup
analysis was to compare the beneficial and harmful effects of perioperative gabapentin treatment in different
surgical procedures.
Methods: Relevant databases were searched for randomized clinical trials (RCTs) comparing gabapentin versus
placebo. Two authors independently screened titles and abstracts, extracted data and assessed risk of bias. The
primary outcomes were differences in 24-h morphine consumption, and serious adverse events (SAE) between
surgical procedures. These subgroup analyses were predefined in a PRISMA compliant systematic review registered
at PROSPERO (ID: CRD42013006538). It was predefined that conclusions should primarily be based on trials classified
as overall low risk of bias.
Results: Seventy-four RCTs with 5645 patients were included, assessing benefit and harm in cholecystectomy,
hysterectomy, mastectomy, and arthroplasty surgery, spinal surgery, and thoracic surgery.
Only eight of 74 trials were classified as overall low risk of bias limiting our ability to conclude on the estimates in
most meta-analyses. The differences between surgical procedures in these trials were not statistically significant
when tested for subgroup differences. Fifteen trials with 1377 patients reported a total of 59 SAEs, most of which
were observed in the thoracic surgery group.
Conclusion: Both beneficial and harmful effects in these subgroup analyses were influenced by bias and
insufficient data, limiting conclusions. With these limitations, we could not adequately test for differences in
beneficial or harmful outcomes between six surgical subgroups undergoing perioperative gabapentin treatment.
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Procedure-specific pain management, Postoperative pain management, Systematic review, Subgroup analyses
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Background
Pain management is a crucial component in postopera-
tive care of the surgical patient. The combination of
non-opioid and opioid analgesics, known as multimodal
analgesia, is a cornerstone in the treatment of postopera-
tive pain. Gabapentin has recently become a part of a
wide array of postoperative multimodal analgesic
regimens [1–3].
It has been argued that postoperative pain treatment
should be “procedure-specific”, that is, adapted to the
particular surgical procedure, since different analgesics
may have specific effects dependent on the nature of the
surgery [4, 5].
Gabapentin has been used in postoperative pain
management since 2002. It is an anti-epileptic drug
presumed to affect nociceptive processing through α2δ-
subunits of voltage gated calcium channels, thereby
causing decrease in excitatory neurotransmitters, e.g.
glutamate, substance P and calcitonin gene-related
peptide (CGRP) [6, 7]. The anti-hyperalgesic properties
have been investigated in several experimental and
clinical trials [8–11].
In a recent systematic review we pooled data from all
clinical trials and different surgical interventions with
gabapentin [12, 13]. The conclusion from this review
was, that firm evidence for use of gabapentin is lacking,
as clinically relevant beneficial effects of gabapentin may
be absent and harm is imminent, especially when added
to multimodal analgesic regimens [12]. In the present
preplanned subgroup analyses and post hoc analyses, we
aimed to compare the procedure-specific effects of peri-
operative gabapentin on postoperative opioid consump-
tion, pain intensity, and adverse- and serious adverse
events in six different surgical procedures. It was our
hypothesis that the reduction in 24-h morphine
consumption and incidence of SAE’s would differ
between surgical procedures.
Methods
These are preplanned subgroup analyses and post hoc
analyses from a systematic review following the meth-
odology recommended by the Cochrane Collaboration.
The protocol was published in the International
Prospective Register of Systematic Reviews (PROS-
PERO) (www.crd.york.ac.uk/PROSPERO) registration
no. CRD42013006538 [13].
Search strategy
The search was planned by a trial search coordinator
using the Cochrane Library’s CENTRAL, PubMed,
EMBASE, and Science Citation Index Expanded data-
bases. Previous reviews, reference lists and Google Scholar
were hand-searched for eligible trials. Www.clinicaltrials.-
gov; www.controlled-trials.com; www.centerwatch.com;
www.eudraCT.com, and at the homepage of the US Food
and Drug Administration (FDA) were searched for un-
published trials. Non-English articles were translated to
English. The electronic search (Additional file 1:
Appendix 1 - search strategies) was last updated April
12th, 2016.
Data extraction
After removal of duplicates, titles and abstracts were
screened by two authors (MLF, AG). MLF and one other
independent author (AG, MSH, PLP, LN) assessed full
texts, extracted data and assessed bias. The following
characteristics were extracted from the trials using a
data extraction form: Year of publication, number of
participants, type of surgery, follow-up period and dose
regimen, consumption of opioid, and non-opioid medi-
cation, pain intensity, and any adverse events described
in the trials, including serious adverse events (SAEs).
The corresponding author was contacted whenever
data were insufficiently reported, and contact was re-
peated after 14 days. In case of no response, the involved
bias domains were classified as unclear.
Risk of bias assessment
Risk of bias was assessed using The Cochrane Handbook
guidelines. All trials were classified as low, unclear or
high risk of bias using the following domains: Random
sequence generation, allocation concealment, blinding,
incomplete outcome data, selective outcome reporting
and other bias, including funding and confirmatory bias.
Disagreements between authors on study selection,
data extraction or bias assessment were solved by OM,
JBD or JW.
We decided a priori to report and conclude based pri-
marily on results from trials classified as low risk of bias.
Small trial size
All trials were evaluated in this post hoc analysis and
allocated to the corresponding group according to the
numbers of participants included in the analyses. Small
trials were defined as trials with less than 50 patients
included in each group. Trials were allocated to the
remaining two groups if they included either more than
50 patients, or more than 200 patients [12].
Analyses
The present subgroup analyses of surgical procedures
were predefined in the protocol investigating the ef-
fect of different surgical procedures: Cholecystectomy,
hysterectomy, mastectomy, orthopedic arthroplasty
surgery, spinal and thoracic surgery on the primary
and secondary outcomes. Analyses of thoracic surgery
and orthopedic arthroplasty surgery have been added
post hoc [13]. The surgical procedures were chosen
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to represent a wide range of surgical interventions
and patient populations. Cholecystectomy is a minor
procedure, often performed as day-case surgery,
whereas thoracic surgery is a major procedure, which
may be associated with intensive care in the im-
mediate postoperative period. Mastectomy and
hysterectomy are procedures with moderate to severe
pain postoperatively. Orthopedic arthroplasty and
spinal surgery often represents patients with chronic
pain preoperatively. We chose to add trials investigat-
ing thoracic surgery and orthopedic arthroplasty
surgery post hoc, in order to broaden the range of
surgical interventions.
The planning and interpretation of the subgroup analyses
followed the direction of the Cochrane Handbook [14].
Outcomes
The primary outcomes were difference in 24-h post-
operative opioid sparing effects, and reported serious
adverse events (SAE) between surgical procedures.
SAE’s were defined according to the International
Conference of Harmonization – Good Clinical
Practice (ICH-GCP) definitions: Medical events being
either life threatening, resulting in death, disability or
significant loss of function, or causing hospital admis-
sion or prolonged hospitalization [15].
Secondary outcomes were differences in early (6-h)
and late (24-h) pain postoperatively, both at rest and
during mobilization, and all other adverse events,
between surgical procedures.
All opioids were converted to intravenous morphine
based upon equivalency as presented in Additional file 1:
Appendix 2. Various scales were used to report pain in-
tensity in the trials. All pain intensity scales reporting
pain levels between 0 and 10 were converted to the
Visual Analogue Scale (VAS) 0 to 100 mm.
Statistical analysis
Review Manager (RevMan) [Computer program],
Version 5.1.6, Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014, and Trial
Sequential Analysis (TSA) software (version 0.9.5.5
Beta), Copenhagen Trial Unit, Denmark, was used for
statistical analyses as predefined in the protocol.
In trials with more than one active treatment arm, in-
cluding trials testing doses delivered pre- and immediate
postoperatively, means and standard deviations were
combined for the intervention groups.
Mean and standard deviations were estimated from
median and range values according to the method de-
scribed by Hozo et al. [16] Standard deviations were cal-
culated by dividing the difference in interquartile ranges
with 1.35 [14].
Longer ordinal scales were analyzed as continuous
data. For dichotomous data, RR with a 95% confidence
interval was calculated.
We examined the heterogeneity between trials using
chi-squared test. The heterogeneity was measured by I2,
which quantifies inconsistencies. If the I2 was greater
than zero the results were calculated using both a fixed
effect model (FEM) and random effect model (REM)
and the most conservative estimation was used [14, 17].
In the case of very few and rare events, Peto’s odd ratio
was used to provide the best coverage of confidence
intervals [18, 19].
Estimates were pooled in meta-analyses whenever
more than one trial was included for the outcome. Tests
for subgroup differences were carried out for all surgical
procedures on all outcomes whenever a meta-analysis
was possible. Using RevMan, the method to test for sub-
group differences was implemented for all types of
meta-analyses [14]. Our test for subgroup differences
was performed on each of the subgroups testing them
for subgroup differences against the compiled, remaining
subgroups using the chi-squared test.
We used Trial Sequential Analysis (TSA) in post hoc
analyses to adjust the confidence intervals for sparse
data and repetitive testing. Minimal clinical relevant dif-
ferences were defined as in our main review [12]. In the
event that the accrued information size was less than 5%
of the required information size, no TSA was reported,
as the TSA program is unable to calculate trial
sequential monitoring boundaries in this situation.
Results
The search strategies revealed 19,137 titles. Duplicates
were removed and 16,303 titles were sorted according to
inclusion- and exclusion criteria. One-hundred-thirty-
five randomized controlled trials and observational
studies were included in the original systematic review.
After excluding 61 trials investigating other surgical
procedures, a total of 74 randomized controlled trials
with 5645 patients were included in the present analyses
(Fig. 1: PRISMA flowchart) [20–94].
Characteristics of included trials
Trial characteristics are presented in Table 1. Eight
trials were classified as overall low risk of bias, [39, 43,
46, 56, 59, 72, 73, 85] 18 trials were overall unclear risk
of bias [21, 23, 24, 26, 28, 29, 31, 36, 38, 42, 52, 54, 55,
61, 65, 66, 68, 69, 80] and 48 trials were classified as
high risk of bias, [20, 22, 25, 27, 30, 32–35, 37, 40, 41,
44, 45, 47–51, 53, 57, 58, 60, 62–64, 67, 70, 71, 74–79,
81–84, 86–94] (Fig. 2: Bias assessment). Allocation
concealment, selective outcome reporting and “other
bias” were the domains with most unclear or high risk
of bias evaluations (Fig. 3: Risk of bias graph).
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Sixty-six trials were classified as small trials [21–27,
29–31, 33–45, 47–55, 57, 58, 61–64, 66, 67, 69, 71–81,
83, 84, 86–94], five had more than 50 participants in
each group [20, 32, 46, 56, 85], and three included more
than 200 patients [59, 68, 70].
The gabapentin dose in the included trials ranged
from 100 mg to 1800 mg, and was mostly administered
as a single dose (46 trials). [20, 22–24, 28–32, 34–37, 41,
43, 45, 47–51, 53, 55–57, 61–64, 67–71, 75, 77–79, 81,
82, 85–90, 92, 94] In 30 trials, gabapentin was adminis-
tered in combination with a basic, non-opioid/opioid an-
algesic regimen [20, 22, 23, 26, 28, 30–32, 37–41, 43, 46,
49, 54, 56, 57, 59, 61, 72, 73, 76, 79, 80, 82, 87, 90, 91].
In 44 trials, gabapentin was administered together with
an opioid as the only analgesic [20, 25, 27, 29, 33–36,
44, 45, 47, 48, 50–53, 55, 58, 62–71, 74, 75, 77, 78, 83–
86, 88, 89, 92–94]. In five trials, gabapentin was adminis-
tered in combination with a NSAID [27, 45, 75, 77, 83],,
and in two trials, the postoperative analgesic regimen
was not described [24, 81].
Bias assessments in surgical subgroups
Eight trials were classified as overall low risk of bias. None
from the mastectomy subgroup and one trial from the
cholecystectomy group was overall low risk of bias [85]. In
the subgroups hysterectomy, [39, 43] and thoracic surgery
[46, 56] two trials were low risk of bias in each group, and
three trials were classified as low risk of bias in the
orthopedic arthroplasty subgroup [59, 72, 73].
Below, we present analyses from trials with low risk of
bias. In addition, analyses from all trials are presented in
Table 2: Primary outcomes from trials with low risk of
bias and all trials estimates, and Table 3: Secondary out-
comes from trials with low risk of bias and all trials
estimate.
Primary outcomes
24-h morphine consumption
24-h morphine consumption was reported in 51 trials
with 4193 patients. [21, 23, 26, 28, 30–33, 35–44, 46,
48–53, 55, 57, 59–63, 65–70, 72, 73, 80, 82, 84–89,
91–93] Of these 51 trials, 7 were classified as overall
low risk of bias [39, 43, 46, 59, 72, 73, 85].
In cholecystectomy, one trial reported a reduction of
12.2 mg [9.8, 14.6] in 24-h morphine consumption in
the gabapentin treatment group compared to controls
[85], two trials in hysterectomy found a reduction of
1.6 mg [−4.8, 8.0] [39, 43], and three trials in ortho-
pedic arthroplasty demonstrated a reduction of 4.0 mg
[−0.8, 8.7] [58, 71, 72]. Finally, one trial in thoracic
surgery reported a reduction of 6.7 mg [−2.0, 15.4] [46].
We found no difference between the surgical
procedures when tested for subgroup differences.
Fig. 1 PRISMA flowchart
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(Table 2: The intervention effect estimated from trials
with low risk of bias, and from all trials despite risk of
bias; Fig. 4: Forest plot of 24-h morphine consumption
from trials with low risk of bias).
(Additional file 1: Appendix 3 - Forest plot of 24-h
morphine consumption from all trials, Additional file 1:
Appendix 4–9 - TSA of estimates from all trials and
cholecystectomy, hysterectomy, mastectomy, orthopedic
arthroplasty, spinal and thoracic surgery groups).
Serious adverse events
Fifteen trials with 1377 patients reported SAEs [20, 33,
34, 38, 39, 44, 46, 49, 53, 56, 59, 72, 85, 91, 92]. Of the
15 trials, 5 were classified as overall low risk of bias [46,
56, 59, 72, 85]. The reported SAEs were: Death, urticarial
rash, re-operation, prolonged admission, re-admission to
hospital, pneumonia, and atrial fibrillation.
One cholecystectomy trial, two orthopedic arthro-
plasty trials, and two thoracic surgery trials were classi-
fied as overall low risk of bias. [46, 56, 59, 72, 85] In the
trials with low risk of bias, the risk of SAE’s were 2.98
[0.36, 24.41] in the orthopedic arthroplasty subgroup
[59, 72] and 1.35 [0.69, 2.63] in the thoracic subgroup
[46, 56]. A comparison of pooled-estimates in test for
subgroup differences from trials with low risk of bias in-
dicated no difference between groups, p = 0.49.
(Table 2: SAEs estimated from trials with low risk of
bias, and from all trials despite risk of bias; Fig. 5: Forest
plot of SAEs from trials with low risk of bias.
(Additional file 1: Appendix 10 - Forest plot of SAEs
in all trials, Appendix 11 - TSA of SAEs in the thoracic
surgery subgroup).
Secondary outcomes
Pain intensity
In general, only few data were available from trials with
low risk of bias, rendering tests for subgroup differences
impossible and/or unreliable.
(Table 3: The intervention effect estimated from tri-
als with low risk of bias, and from all trials despite
risk of bias).
(Additional file 1: Appendix 12–15 - Forest plots of
VAS 6 h postoperative at rest and mobilization, 24 h
postoperative at rest and mobilization, all trials
estimates).
Adverse events
No subgroup differences were demonstrated in any
adverse event in trials with low risk of bias.
(Table 3: Adverse events estimated from trials with
low risk of bias, and from all trials despite risk of bias).
(Additional file 1: Appendix 16–19 - Forest plots of
nausea, vomiting, sedation and dizziness, all trials).
Fig. 2 Risk of bias assessment. Risk of bias graph: The ‘Other’ bias
domain is an evaluation of risk of financial bias and confirmatory bias
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Discussion
It has been argued that postoperative pain treatment
should be “procedure-specific”, since different analgesics
may have specific effects dependent on the surgical
procedure [4, 5]. In the present, preplanned subgroup
analyses, we aimed to compare the effects of perioperative
gabapentin on postoperative opioid consumption, pain
intensity, and adverse- and serious adverse events in six
different surgical procedures. Our primary outcomes were
24-h morphine consumption and the risk of SAEs.
Our results are limited by the fact that overall, only
eight trials were classified as overall low risk of bias,
limiting our ability to test for subgroup differences, and
to pool estimates in meta-analyses of these eight trials.
When interpreting the results from the all trials analyses,
it should be noted that about two-thirds of these trials
had overall high risk of bias, which is a severe limitation
to any conclusion on the outcomes.
In trials with low risk of bias, 24-h morphine con-
sumption varied, and only the cholecystectomy subgroup
indicated a difference between groups. With only one
trial in this subgroup, the result has not been repro-
duced, and is difficult to interpret.
For the analysis of all trials, the difference in 24-h
morphine consumption between surgical procedures was
not statistically significant, when tested for subgroup dif-
ferences. A reduction in 24-h morphine consumption
was demonstrated for all surgical procedures compared
with controls. However, the TSA did not reach required
information size in any subgroup. Consequently, the ef-
fects observed in the individual procedures may be due
to both random and systematic error, as indicated in the
main systematic review [12].
SAEs were primarily reported in the thoracic surgery
trials but overall, since SAEs were very poorly reported
and data was sparse, it is not possible to conclude on
this outcome.
For pain intensity outcomes, very few data were avail-
able from trials with low risk of bias. In the analyses of
data from all trials, the results were divergent across sur-
gical subgroups, and it is difficult to interpret the
direction and authenticity in the test for subgroup
differences.
No subgroup difference was demonstrated for any
adverse event in trials with low risk of bias, and re-
sults from data including all trials were divergent
across surgical subgroups, with no consistent differ-
ences in adverse events between surgical procedures.
This indicates a similar adverse event profile of gaba-
pentin for postoperative pain management irrespective
of surgical procedure. Much like the previous out-
comes, there is far too few data to firmly conclude
based on these results. Poor reporting and high risk
of bias limits any interpretation.
Strengths and limitations of the subgroup analyses
These subgroup analyses have some strength. The ana-
lyses were planned in a PROSPERO published protocol,
and were derived from a PRISMA compliant systematic
review adhering to Cochrane standards in methodology
and bias assessment. The trials have been critically
assessed using the Cochrane bias assessment tools, and
conclusions are based on trials with low risk of bias,
which is unlike most of the previous systematic reviews.
The TSA has been added to adjust for sparse data and
repetitive resting, which is a risk when the vast majority
of included trials are small, that is <50 patients in each
group [95–98].
The limitations of this analysis mirror those of the in-
cluded trials, and the limitations of the general method-
ology in subgroup analyses. Subgroup comparisons are
to be perceived as observational because we compare
pre-existing non-randomized groups, and must be inter-
preted as such [14].
The critical assessment of the trial methodology shows
a very small number of trials with overall low risk of
bias. Eighty-nine percent of the included trials have un-
clear or high risk of bias in one of the bias domains or
more, risking an overestimation of beneficial -, and
underestimation of harmful outcomes.
Despite the larger number of included trials in each
subgroup compared with previous published systematic
Fig. 3 Risk of bias graph. Risk of bias summary
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reviews, there is still a risk of spurious results due to
lack of sufficient data. The lack of statistically significant
p-values in the present subgroup analyses may be due to
a small effect size, or poor power to detect a large effect.
According to Oxman and Guyatt [99], Xin Sun et al
[100] and their criteria to evaluate the credibility of sub-
group analyses, we have to consider further limitations
such as: If the subgroup can be considered independent;
no a-priori direction of the subgroup effect has been
published; the subgroup effects found in our analyses
does not seem to consequently manifest in closely
related outcomes.
Relation to the previously published systematic reviews
A number of systematic reviews investigating indivi-
dual surgical procedures, or with a procedure specific
approach, have been published [95–98, 101–103].
Overall, there are some general methodological differ-
ences that separates the present work from previously
published systematic reviews, such as: The emphasis
on trials with low risk of bias, subgroup analyses with
test for subgroup differences, and the use of trial se-
quential analyses. The emphasis on trials with low
risk of bias prevents any direct comparison with esti-
mates from other systematic reviews. Several reviews
have evaluated bias in the included trials, and report
different overall bias evaluations and number of trials
with overall low risk of bias, compared to the present
review [97, 98, 104]. This may be explained by the
fact that that we contacted every author whenever a
bias domain was deemed unclear risk of bias, to give
them a chance to describe their methods in greater
detail. To our knowledge, this was not done in the
previously published systematic reviews.
In a recent review, the effect of trials with high risk of
bias were tested using sensitivity analyses, and no impact
was demonstrated on the outcomes [104]. This is in
contrast to the present analyses, and to the findings
of our recently published systematic review [12, 104].
The different approach to author contact, and a dif-
ferent statistical approach, may explain some of the
differences in the findings. Further, the systematic
Fig. 4 Forest plot of 24-h morphine consumption. Forest plot of 24-h morphine consumption of trials with overall low risk of bias
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review by Doleman et al. [104] reports that the type
of surgery was not independently associated with the
effect of gabapentin, which may provide some
confirmation of the results from the present analyses.
However, the results are obtained with different
statistical approaches and the number and types of
surgeries are not stated in the findings from Doleman
et al. Consequently, the confirmation must be
interpreted with caution [104]. In another review,
Mathiesen et al. demonstrated a greater beneficial
effect (reduction in 24-h opioid consumption) in their
hysterectomy and spinal surgery groups [95], which
seems similar to the results from the all trials esti-
mates in Table 2 in the present review. Mathiesen et
al., however, did not test for subgroup differences
[95], and we found no differences between subgroups
in the all trials estimates of the present review.
Most previous systematic reviews report favorable
results for gabapentin treatment, similar to the find-
ings from the all trials estimates in the subgroup
analyses of the present review. In comparison with
the systematic reviews of gabapentin for hysterec-
tomy, cholecystectomy and thoracic surgeries [95,
96, 101], more trials have been included in our sub-
groups. Due to different inclusion criteria and sub-
group analyses in the different published systematic
reviews, it is not possible to conduct a full compari-
son of estimates.
However, none of the systematic reviews above have
investigated the risk of SAEs, limiting the ability to
Fig. 5 Forest plot of serious adverse events. Forest plot of Serious Adverse Events of trials with overall low risk of bias
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weigh the benefit and harm of gabapentin in periopera-
tive pain management [95–98, 101].
Impact of the analyses
We observed no systematic differences in postoperative
opioid consumption, pain intensity, or adverse- or
serious adverse events between six different surgical
procedures treated with peri-operative gabapentin.
SAEs were very poorly reported, and only half the
subgroups reported this outcome. More than 80% of the
SAEs were reported in the thoracic surgery trials, mak-
ing it impossible to rely on the risk and subgroup differ-
ences between the surgical procedures. In the original
review, excess SAEs were reported in the gabapentin
versus control groups, and approximately twice as many
SAEs were found in trials with low risk of bias, com-
pared with all trials [13]. Most trials have a short follow-
up period and only report on SAEs and adverse effects
for a short period postoperatively, which seems insuffi-
cient for a full evaluation. The inconsequent and diverse
reporting of SAEs and adverse events complicates any
reliable evaluation of these outcomes.
Conclusion
Both beneficial and harmful effects in the present sub-
group analyses are influenced by bias and insufficient data,
limiting any conclusion. The very poorly reported inci-
dence of SAEs limits any conclusion based on this out-
come. Because of these limitations, we could not properly
test for any major differences in beneficial or adverse out-
comes between various surgical subgroups with gabapentin
for postoperative pain. Consequently, our analyses cannot
confirm or reject the concept of a procedure specific effect
of gabapentin on postoperative pain.
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